Recent

% | $
Quotes you view appear here for quick access.

Mast Therapeutics, Inc. Message Board

  • serenityloveh69@att.net serenityloveh69 Sep 20, 2013 8:41 PM Flag

    Really... This will be ok @ .25 .30 cents The pumper's will be able to average down again & again

    With all the new names pretending to be new sheep are basically all the same old fleeced bag holders. Really very amusing to say the least.
    Come on now you old secluded investors fess up and come clean.

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • thebigmonkey@sbcglobal.net thebigmonkey Oct 14, 2013 9:30 PM Flag

      RISKS RELATED TO OUR BUSINESS

      Risks Related to Our Capital Requirements, Finances and Operations

      We have incurred losses since our inception, we expect our operating expenses to continue to exceed our revenue for the foreseeable future, and we may never generate revenue sufficient to achieve profitability.

      We are a development-stage company and have not generated sustainable revenue from operations or been profitable since inception, and we may never achieve profitability. We have devoted our resources to acquiring and developing proprietary product candidates, but such product candidates cannot be marketed until the regulatory process is completed and governmental approvals have been obtained. We have accumulated net losses totaling approximately $192.8 million as of March 31, 2013, and we expect to continue to incur substantial operating losses for the next several years .....

      Sentiment: Strong Sell

    • Mast Therapeutics (MSTX) focuses on developing therapies for serious or life-threatening diseases. Its lead product candidate includes MST-188, a product candidate that has hemorheologic, cytoprotective, and anti-inflammatory properties, which is in phase 3 study for the treatment of sickle cell disease in patients. I rarely cover stocks that sell for less than $1 a share, but I will make an exception for this speculative biotech play.

      One very interesting thing about Mast is that its entire market capitalization is represented by the net cash on its balance sheet after a recent secondary offering. The other thing that caught my eye on this stock was a report from Canaccord Genuity this week on this fifty cent a share stock. The analyst firm initiated the shares with a whopping $3 a share price target. Its analyst noted "We think MST-188 could gain significant market share given the unmet need in SCD and potential combo-Tx. Our $3.00 target is based on NPV analysis."

      This is a speculative play for patient long term investors. Even Canaccord's analyst does not see a launch of MST-188 until 2017, although he also puts eventual peak sales at $400mm annually. Only three analysts cover this ~$50mm market capitalization concern. Their price targets range from $1 to $3 a share.

      Sentiment: Strong Buy

    • thebigmonkey@sbcglobal.net thebigmonkey Oct 10, 2013 2:01 PM Flag

      Ditto

      Sentiment: Strong Sell

    • thebigmonkey@sbcglobal.net thebigmonkey Sep 26, 2013 10:11 PM Flag

      ROTFLMAO

      Sentiment: Strong Sell

    • thebigmonkey@sbcglobal.net thebigmonkey Sep 26, 2013 1:20 PM Flag

      Baaaaaaa

      Sentiment: Strong Sell

    • serenityloveh69@att.net serenityloveh69 Sep 23, 2013 2:48 AM Flag

      Ditto

      Sentiment: Strong Sell

 
MSTX
0.39-0.0059(-1.49%)Aug 26 4:01 PMEDT